Navigation Links
Genesis Pharmaceuticals Changes Auditors
Date:3/11/2008

LAIYANG, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, announced that it changed auditors from Sherb & Co., LLP to Moore Stephens Wurth Frazer & Torbet, LLP.

The client-auditor relationship between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP ended as of February 25, 2008 in regard to all accounting and auditing services, and all quarterly reporting up through and including February 25, 2008. All accounting and auditing services and all quarterly reports from February 25, 2008 on will be handled by Moore Stephens Wurth Frazer & Torbet, LLP. Sherb & Co., LLP, were Genesis' auditors for the fiscal years ended September 30, 2007 and September 30, 2006. There were no disagreements between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP.

"We look forward to working with Moore Stephens and continuing to provide the investment community with timely and accurate financial information that reflects Genesis' activities," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc.

About Genesis Pharmaceuticals Enterprises

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged through its controlled affiliates in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal- based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung CFO

Tel: +1-877-895-3650 x701

Email: genesispharm@gmail.com

CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
2. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
3. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
4. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
5. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
6. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
7. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
8. ThermoGenesis Corp. Reports First Quarter 2008 Results
9. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
10. Researchers chart the genetic mechanisms behind the genesis of fat cells
11. Genesis Technology Group Retains CCG Elite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle ... in Jefferson County, is announcing the launch of a charity drive to raise ... of homeless women and children in Birmingham has grown steadily since the 1980’s, ...
(Date:12/8/2016)... ... 08, 2016 , ... The Compretta Insurance Agency, a family owned insurance and ... the Hancock County area, is announcing the launch of a charity effort aimed at ... County Food Pantry has worked for more than 30 years to meet the food ...
(Date:12/7/2016)... OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... clinical trials with the announcement that it is one of the early adopters completing ... Privacy Shield Framework is designed to provide companies on both sides of the Atlantic ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader ... through a new partnership with Splashtop Inc. This remote control for Android extends ... help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Boehringer Ingelheim announced today that it has been recognized ... the ninth time that the company received a perfect ... to Work for LGBT Equality. Administered by the Human ... report on corporate policies and practices related to workplace ... "We are committed to creating an ...
(Date:12/8/2016)... , Dec. 8, 2016  Avelas Biosciences, ... improving cancer patient care from diagnosis through treatment, ... recently completed Phase 1b study in breast cancer ... San Antonio Breast Cancer Symposium. Jonathan Unkart ... at UC San Diego Health, delivered the presentation ...
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology: